SynthesisImmunity, inflammation and disease2023

Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.

Xuezhi Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.